Showing 1-10 of 44 "Cancers and Other Neoplasms"

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Ramon Guardiola

Phone: 713.441.3958

This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). This is a multi-center, open-label Phase Ib study. The ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

The objective of this study is to evaluate the safety and efficacy of FS VH S/D 500 s-apr for use as an adjunct to sutured dural repair in cranial surgery (NCT02891070). ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor (HER2)-amplified BC. An open label Phase 1b clinical study (REP0111) is ongoing (enrollment completed) in fi ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spr ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Pamela Weaver

Phone: 713.441.3834

Purpose This is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing doses of Toca 511, a Retroviral Replicating Vector (RRV), administered to subjects with recurrent high grade glioma (rHGG) who have u ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

This open-label, multicenter, global study is designed to determine the recommended phase 2 dose, safety, efficacy, and pharmacokinetics/pharmacodynamics of durvalumab in subjects with certain lymphoma subtypes or CLL. Globally, 253 subjects may ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Status: Enrolling

Investigator: Brian Miles

Study Coordinator: Vivian MacDonnell

Phone: 714.441.8113

This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate cancer. Subjects enrolled will be diagnosed with localized prostat ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The main purpose of this study is to compare nivolumab and ipilimumab with the Extreme study regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improveme ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before nivolumab in patients with metastatic squamous and non-squamous ... Read more >

Status: Open Not Enrolling

Investigator: Daniel Lehane

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplati ... Read more >

Status: Open Not Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether paclitax ... Read more >

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously treated stage II, stage III, or stage IV ovarian ... Read more >

Status: Open Not Enrolling

Investigator: Daniel Lehane

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x- ... Read more >

Status: Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC; i.e., tumors lacking expression of estrogen, pr ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment appr ... Read more >

Status: Enrolling

Investigator: Daniel Lehane

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Pamela Weaver

Phone: 713.441.3834

Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site pr ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer. ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Ramon Guardiola

Phone: 713.441.3958

An oral formulation of azacitidine (CC-486) has been developed and is currently in clinical trials for the treatment of hematologic and solid tumor malignancies. The oral formulation will provide an opportunity to deliver the drug daily over a m ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects u ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to ev ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The primary objective is to evaluate the safety and tolerability of IMMU-132 as a single agent administered in 3-week treatment cycles for up to 8 cycles, in previously treated patients with advanced epithelial cancer. IMMU-132 targets the TROP- ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple neg ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study "Master Protocol". The type ... Read more >

Status: Enrolling

Investigator: Rafik Ghobrial

Study Coordinator: Susan Dorman

Phone: 713.441.6316

The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option f ... Read more >

Status: Enrolling

Investigator: Mark Sultenfuss

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal Radiation-Spheres (SIR-spheres ... Read more >